⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 4, 2018Alzheimer s & Dementia

Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

View Full Paper

Ask AI

Bookmark

Share

Abstract

Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mielke et al. (2018) studied this question.

synapsesocial.com/papers/69dcd1230de68e8319e53a52 https://doi.org/10.1016/j.jalz.2018.02.013

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Agingcohort · 2017 · 217 citations
2Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97Original Research · 1992 · 454 citations
3Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob DiseaseRegistry Study · 2014 · 209 citations
4Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric ApproachOriginal Research · 1988 · 23,152 citations
5Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndromePilot Study · 2017 · 273 citations